Literature DB >> 20571403

Retinol supplementation and mesothelioma incidence in workers earlier exposed to blue asbestos (Crocidolite) at Wittenoom, Western Australia.

Helman S Alfonso1, Alison Reid, Nicholas H de Klerk, Nola Olsen, Robin Mina, Gina L Ambrosini, John Beilby, Geoffrey Berry, Bill A W Musk.   

Abstract

Owing to the high rates of malignant mesothelioma in workers exposed to crocidolite earlier at Wittenoom and evidence of protection against cancer by vitamin A, a population-based cancer prevention programme providing retinol supplements (25 000 IU/day) was commenced in 1990. The former workers at Wittenoom known to be alive and living in Western Australia in June 1990 constitute the study population. The participants were classified into two groups: those who received supplemental retinol (intervention group) and those who received none (comparison group). The relative rate of mesothelioma for those receiving retinol was estimated using Cox regression, adjusting for cumulative asbestos exposure and age at first exposure to asbestos. Nine hundred and twenty-eight former Wittenoom workers received retinol at some stage of the programme, whereas 1471 workers never received retinol (comparison group). Those who received retinol were younger, had a greater exposure to asbestos and smoked less than the comparison group. There were 65 cases of mesothelioma in the retinol group and 88 in the comparison group. After adjustment, the hazard ratio was 0.99 (95% confidence interval=0.70-1.41). This result did not alter when the participants who received only retinol once or those who received beta-carotene earlier were excluded from the analysis. In conclusion, this study provides little support for possible preventive effects of retinol against mesothelioma in workers exposed to blue asbestos.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571403     DOI: 10.1097/CEJ.0b013e32833c1bcb

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  4 in total

1.  Malignant pleural mesothelioma: some progress, but still a long way from cure.

Authors:  Loic Lang-Lazdunski
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 2.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

3.  Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up.

Authors:  G Berry; A Reid; P Aboagye-Sarfo; N H de Klerk; N J Olsen; E Merler; P Franklin; A W Musk
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

4.  Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans.

Authors:  Cleo Robinson; Helman Alfonso; Samantha Woo; Amy Walsh; Nola Olsen; Arthur W Musk; Bruce W S Robinson; Anna K Nowak; Richard A Lake
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.